Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure | Linko et al. Critical Care 2010 14 R60 http content 14 2 R60 c CRITICAL CARE RESEARCH Open Access One-year mortality quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure Rita Linko 1 Raili Suojaranta-Ylinen1 Sari Karlsson2 Esko Ruokonen3 Tero Varpula1 Ville Pettila4 and the FINNALI study investigators Abstract Introduction High daily intensive care unit ICU costs are associated with the use of mechanical ventilation MV to treat acute respiratory failure ARF and assessment of quality of life QOL after critical illness and cost-effectiveness analyses are warranted. Methods Nationwide prospective multicentre observational study in 25 Finnish ICUs. During an eight-week study period 958 consecutive adult ICU patients were treated with ventilatory support over 6 hours. Of those 958 619 survived one year of whom 288 answered the quality of life questionnaire EQ-5D . We calculated EQ-5D index and predicted lifetime quality-adjusted life years QALYs gained using the age- and sex-matched life expectancy for survivors after one year. For expired patients the exact lifetime was used. We divided all hospital costs for all ARF patients by the number of hospital survivors and by all predicted lifetime QALYs. We also adjusted for those who died before one year and for those with missing QOL to be able to estimate the total QALYs. Results One-year mortality was 35 95 CI 32 to 38 . For the 288 respondents median IQR EQ-5D index after one year was lower than that of the age- and sex-matched general population to vs. to . For these 288 the mean SD predicted lifetime QALYs was . After adjustment for missing QOL the mean predicted lifetime SD QALYs was for all the 958 ARF patients. The mean estimated costs were per hospital survivor and mean predicted lifetime cost-utility for all ARF patients was 1391 per QALY Conclusions Despite lower health-related
